The purpose of this research is to determine if this treatment method is practical and safe for people with CRPS affecting either one arm or one leg. The study will involve participants receiving injections of Xeomin directly near the affected nerves. Each participant may receive up to 200 units of the medication, and the treatment period may last up to 12 months.

During the study, researchers will collect information about how participants respond to the treatment and any symptoms that occur after the injections. This information will help determine whether larger studies of this treatment should be conducted in the future. The study is designed as an open-label study, which means all participants will receive the active medication, and there will be no comparison group.

Participants in the study will receive esketamine through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a total of three months, during which participants will receive the infusions in a day treatment setting. The researchers aim to assess the impact of this treatment on pain levels and other symptoms associated with CRPS. The study will also monitor any side effects that may occur during the treatment period.

Throughout the study, participants’ pain intensity will be measured using a simple scale, and the effects of the treatment on inflammation and other symptoms will be evaluated. The study will also look at how the treatment affects the need for other pain medications and any changes in CRPS symptoms over time. The goal is to provide valuable information on the effectiveness and safety of esketamine infusions for managing CRPS, potentially offering a new approach to treatment for those affected by this challenging condition.

Participants in the study will receive either fremanezumab or a placebo over a period of eight weeks. The study will monitor changes in pain intensity from the beginning to the end of the treatment period. Pain levels will be assessed using a numeric scale, where patients rate their pain from 0 (no pain) to 10 (worst possible pain). The study will also evaluate other aspects of CRPS, such as pain relief and the severity of symptoms, to understand the overall impact of fremanezumab on the condition.

In addition to fremanezumab, the study involves the use of sodium chloride as a solution for infusion. This is a common substance used in medical treatments to help maintain fluid balance in the body. The trial is designed to provide insights into how fremanezumab can potentially help manage pain in CRPS patients, offering a new avenue for treatment in this challenging condition.

Participants in the study will be given either L-Ascorbic Acid, which is another name for Vitamin C, or a placebo. The Vitamin C will be provided in capsule form, and the study will monitor the participants for up to six months after their surgery to check for any signs of CRPS Type I. The study will also look at how well participants tolerate Vitamin C and how closely they follow the treatment plan.

In addition to the main focus on CRPS Type I, the study will gather information about the population affected by this condition and will continue to observe participants for up to twelve months after surgery. This will help researchers understand more about the long-term effects of Vitamin C on CRPS Type I and its potential benefits in preventing this painful condition.